WallStreetZenWallStreetZen

NASDAQ: PBYI
Puma Biotechnology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PBYI stock forecasts and price targets.

Forecast return on equity

Is PBYI forecast to generate an efficient return?

Company
20.21%
Industry
85.8%
Market
169.74%
PBYI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PBYI forecast to generate an efficient return on assets?

Company
13.47%
Industry
29.42%
PBYI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PBYI earnings per share forecast

What is PBYI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.30-40.84%
Avg 2 year Forecast
$0.20-59.2%
Avg 3 year Forecast
$0.12-75.52%
PBYI's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

PBYI revenue forecast

What is PBYI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$226.4M-0.32%
Avg 2 year Forecast
$223.4M-1.67%
Avg 3 year Forecast
$220.3M-3.02%
PBYI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PBYI earnings growth forecast

How is PBYI forecast to perform vs Biotechnology companies and vs the US market?

Company
-37.73%
Industry
15.87%
Market
33.38%
PBYI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
PBYI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
PBYI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

PBYI revenue growth forecast

How is PBYI forecast to perform vs Biotechnology companies and vs the US market?

Company
-1.02%
Industry
36.05%
Market
13.75%
PBYI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PBYI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PBYI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PBYI$7.05N/AN/A
IRD$4.29$10.56+146.06%Strong Buy
RGNX$6.75$25.00+270.37%Strong Buy
PALI$2.01$10.50+422.39%Strong Buy
OABI$2.55N/AN/A
View Top Biotech Stocks

Puma Biotechnology Stock Forecast FAQ

What is PBYI's earnings growth forecast for 2026-2028?

(NASDAQ: PBYI) Puma Biotechnology's forecast annual earnings growth rate of -37.73% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Puma Biotechnology's earnings in 2026 is $24,384,000.On average, 3 Wall Street analysts forecast PBYI's earnings for 2026 to be $15,056,059, with the lowest PBYI earnings forecast at $14,465,625, and the highest PBYI earnings forecast at $15,498,884. On average, 3 Wall Street analysts forecast PBYI's earnings for 2027 to be $10,383,489, with the lowest PBYI earnings forecast at $9,976,293, and the highest PBYI earnings forecast at $10,688,886.

In 2028, PBYI is forecast to generate $6,230,093 in earnings, with the lowest earnings forecast at $5,985,776 and the highest earnings forecast at $6,413,331.

If you're new to stock investing, here's how to buy Puma Biotechnology stock.

What is PBYI's revenue growth forecast for 2026-2028?

(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of -1.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Puma Biotechnology's revenue in 2026 is $227,178,000.On average, 3 Wall Street analysts forecast PBYI's revenue for 2026 to be $11,525,672,817, with the lowest PBYI revenue forecast at $11,073,685,647, and the highest PBYI revenue forecast at $11,864,663,194. On average, 3 Wall Street analysts forecast PBYI's revenue for 2027 to be $11,369,920,481, with the lowest PBYI revenue forecast at $10,924,041,247, and the highest PBYI revenue forecast at $11,704,329,907.

In 2028, PBYI is forecast to generate $11,214,168,146 in revenue, with the lowest revenue forecast at $10,774,396,846 and the highest revenue forecast at $11,543,996,621.

What is PBYI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PBYI) forecast ROA is 13.47%, which is lower than the forecast US Biotechnology industry average of 29.42%.

What is PBYI's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PBYI) Puma Biotechnology's current Earnings Per Share (EPS) is $0.50. On average, analysts forecast that PBYI's EPS will be $0.30 for 2026, with the lowest EPS forecast at $0.28, and the highest EPS forecast at $0.30. On average, analysts forecast that PBYI's EPS will be $0.20 for 2027, with the lowest EPS forecast at $0.20, and the highest EPS forecast at $0.21. In 2028, PBYI's EPS is forecast to hit $0.12 (min: $0.12, max: $0.13).

What is PBYI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PBYI) forecast ROE is 20.21%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.